Fast-growing specialist sterile manufacturing and Contract Manufacturing Organisation (CMO) Symbiosis Pharmaceutical Services (Symbiosis), has expanded its sterile biologics manufacturing facility in Scotland, UK by 25%. In the last 12 months Symbiosis has invested over £1.5m ($1.9m) in the expansion of its Stirling site, doubling its current footprint with an additional 8,000 sq ft of office space to house the firm’s administrative, management and operational teams...
Working in collaboration with teams at the German Cancer Research Center and the Pivot Park Screening Centre as part of the European Lead Factory project, BioAscent scientists have helped to discover potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases. The findings have been published in ChemMedChem and represent an initial step in the development of potential new cancer treatments. The...
A University of Dundee discovery has the potential to help scientists better understand neurological diseases such as Alzheimer’s and Parkinson’s. Researchers, led by Professor Daan van Aalten in the University’s School of Life Sciences, have developed a new way to tag proteins in human cells with a small sugar molecule called O-GlcNAc. There are over 20,000 proteins in every human cell and approximately 20% of...
Thermo Fisher Scientific, the world leader in serving science, today announced that it is investing nearly $24 million in its Inchinnan, Scotland, site to expand global bioproduction capabilities with additional large-volume liquid manufacturing capacity for cell culture media. Thermo Fisher’s high-quality liquid products, including cell culture media, supplements, process liquids, water and buffers, are used throughout the upstream and downstream bioprocessing workflow. “More and more customers are outsourcing their...
Glasgow scientists have been awarded a major cash boost from Cancer Research UK to pioneer new radiotherapy technologies and techniques that could help more people survive cancer in the future. Experts from the Cancer Research UK Glasgow Centre* are set to receive £3.5 million over the next five years. Glasgow has been chosen to be one of just seven centres of excellence in a UK-wide...
Edinburgh-based biotechnology company MedAnnex Ltd has announced that Dr Stefan Symeonides, a Senior Clinical Lecturer at the University of Edinburgh, will provide expert advice as the company prepares for Phase I clinical trials. Dr Symeonides is a Phase I trial specialist with a focus on immunotherapy and leads the Edinburgh Cancer Centre Phase I trials unit. The collaboration between MedAnnex and Dr Symeonides has been...